Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
A phase 3 trial of Degarelix, Goserelin / leuprolide and Bicalutamide in Prostate cancer, run by Ferring Pharmaceuticals, completed.
Overview
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer is a phase 3 interventional study registered as NCT00833248 by Ferring Pharmaceuticals, with 246 participants recorded, started 2009-04 and reaching its primary completion in 2011-09. Interventions recorded: Degarelix, Goserelin, Bicalutamide. Conditions recorded: Prostate Cancer.
Linked to the drug Degarelix because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialInvestigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
Shares Ferring Pharmaceuticals, Degarelix, Bicalutamide, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
- TrialA Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
Shares Ferring Pharmaceuticals, Degarelix, Prostate cancer and the tag pipeline.
- TrialRadiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Shares Degarelix, Bicalutamide, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
- TrialHormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
Shares Bicalutamide, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
- TrialProstate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Shares Bicalutamide, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
- TrialTwo Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Shares Degarelix, Bicalutamide, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
- TrialStandard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Shares Degarelix, Bicalutamide, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
- TrialAssessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Shares Degarelix, Bicalutamide, Prostate cancer and the tag pipeline.